Almotriptan for menstrually related migraine

Bibliography

• Lipton RB, Bigal ME, Diamond M, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Brandes J, Eikermann A, Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey – Phase III. Curr Med Res Opin 2004;20:1143-50
   PubMed Web of Science ®Google Scholar
• Wober C, Brannath W, Schmidt K, PAMINA Study Group. Prospective analysis of factors relate to migraine attacks: the PAMINA study. Cephalalgia 2007;27:304-14
   PubMed Web of Science ®Google Scholar
• Leone M, Vila C, McGown C. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study. Expert Rev Neurother 2010;10:1399-408
   PubMed Web of Science ®Google Scholar
• MacGregor EA. ‘Menstrual’ migraine: towards a definition. Cephalalgia 1996;16:11-21
   PubMed Web of Science ®Google Scholar
• Martin V, Lipton R. Epidemiology and biology of menstrual migraine. Headache 2008;48:S124-30
   PubMed Web of Science ®Google Scholar
• Loder E, Marcus DA. Migraine in women. Decker BC; Hamilton: 2004
   Google Scholar
• Granella F, Sances G, Allais G, Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine referred to headache centers. Cephalalgia 2004;24:707-16
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Victor TW, Hu X, Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache 2010;50:528-38
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Chee E, Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517-23
   PubMed Web of Science ®Google Scholar
• MacGregor A, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351-3
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24:S9-169
   PubMedGoogle Scholar
• MacGregor A. Migraine in women. Martin Dunitz Ltd; London: 1999
   Google Scholar
• Somerville BW. Estrogen-withdrawal migraine: I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975;25:239-44
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154-8
   PubMed Web of Science ®Google Scholar
• Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache 2006;46:S49-54
   Google Scholar
• Nattero G, Allais G, De Lorenzo C, Menstrual migraine: new biochemical and psychological aspects. Headache 1988;28:103-7
   PubMed Web of Science ®Google Scholar
• Nattero G, Allais G, De Lorenzo C, Relevance of prostaglandins in true menstrual migraine. Headache 1989;29:233-8
   PubMed Web of Science ®Google Scholar
• Fioroni L, Martignoni A, Facchinetti F. Changes of neuroendocrine axes in patients with menstrual migraine. Cephalalgia 1995;15:297-300
   PubMed Web of Science ®Google Scholar
• Fioroni L, D'Andrea G, Alecci M, Platelet serotonin pathway in menstrual migraine. Cephalalgia 1996;16:427-30
   PubMed Web of Science ®Google Scholar
• Benedetto C, Allais G, Ciochetto D, Pathophysiological aspects of menstrual migraine. Cephalalgia 1997;17:S32-4
   PubMed Web of Science ®Google Scholar
• Silberstein SD. The role of sex hormones in headache. Neurology 1992;42:37-42
   PubMed Web of Science ®Google Scholar
• MacGregor A. Menstruation, sex hormones and migraine. Neurol Clin 1997;15:125-41
   PubMed Web of Science ®Google Scholar
• Couturier EG, Bomhof MA, Neven AK, Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-8
   PubMed Web of Science ®Google Scholar
• Martin VT, Wernke S, Mandell K, Defining the relationship between ovarian hormones and migraine headache. Headache 2005;45:1190-201
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Kilminster SG, Salt R, Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: a general practice study. Headache 2005;45:274-82
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Messa G, Treatment of menstrual migraine. Cephalalgia 1997;17:S35-8
   PubMed Web of Science ®Google Scholar
• MacGregor A. Migraine associated with menstruation. Funct Neurol 2000;15:S143-53
   PubMed Web of Science ®Google Scholar
• Visser WH, Jaspers NM, de Vriend RH, Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996;16:264-9
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Massiou H, McCarroll KA, Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002;42:917-23
   PubMed Web of Science ®Google Scholar
• Diamond ML, Cady RK, Mao L, Characteristic of migraine attacks and response to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache 2008;48:248-58
   PubMed Web of Science ®Google Scholar
• Pinkerman B, Holroyd K. Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine. Cephalalgia 2010;30:1187-94
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
   PubMed Web of Science ®Google Scholar
• Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993;82:769-72
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Bonellie G, Kangasniemi P, The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol 1995;86:911-16
   PubMed Web of Science ®Google Scholar
• Gross MLP, Barrie M, Bates D, The efficacy of oral sumatriptan in menstrual migraine: a prospective study. Cephalalgia 1995;15:S227
   Google Scholar
• Nett R, Landy S, Shackelford S, Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-42
   PubMed Web of Science ®Google Scholar
• Landy S, Savani N, Shackelford SJ, Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract 2004;58:913-19
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 2005;6:81-7
   PubMedGoogle Scholar
• Mannix LK, Martin VT, Cady RK, Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114:106-13
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Allais G, Nappi RE, Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecol Endocrinol 2010;26:773-9
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Massiou H, Le Jeunne C, Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000;96:237-42
   PubMed Web of Science ®Google Scholar
• Massiou H, Silberstein SD, McCarrol KA, Efficacy of rizatriptan in menstrual migraine: freedom from pain and associated symptoms at 2-h and 24-h sustained pain free status [abstract]. Cephalalgia 2000;20:343-4
   Google Scholar
• Silberstein SD, Massiou H, McCarroll KA, Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002;42:917-23
   PubMed Web of Science ®Google Scholar
• Mannix LK, Loder E, Nett R, Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 2007;27:414-21
   PubMed Web of Science ®Google Scholar
• Bigal M, Sheftell F, Tepper S, A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache 2008;48:1286-93
   PubMed Web of Science ®Google Scholar
• Nett R, Mannix LK, Mueller L, Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache 2008;48:1194-201
   PubMed Web of Science ®Google Scholar
• Martin V, Cady R, Mauskop A, Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache 2008;48:226-35
   PubMed Web of Science ®Google Scholar
• Silberstein S. Zolmitriptan is effective in the treatment of menstrually associated migraine attacks. Cephalalgia 2001;21:420
   Google Scholar
• Loder E, Silberstein SD, Abu-Shakra S, Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44:120-30
   PubMed Web of Science ®Google Scholar
• Tuchman M, Hee A, Emeribe U, Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20:1019-26
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27:S193-7
   PubMed Web of Science ®Google Scholar
• Allais G, Bussone G, D'Andrea G, Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2011;31:144-51
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Benedetto C, Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci 2010;31:S115-19
   Google Scholar
• Bou J, Domenech T, Puig J, Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000;410:33-41
   PubMed Web of Science ®Google Scholar
• Bou J, Gras J, Cortijo J, Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21:804-12
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Lambert GA, Donaldson C, The 5-hydroxytry ptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res 2004;998:91-9
   PubMed Web of Science ®Google Scholar
• Gras J, Bou J, Llenas J, Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000;410:43-51
   PubMed Web of Science ®Google Scholar
• Salva M, Jansat JM, Martinez-Tobed A, Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 2003;31:404-11
   PubMed Web of Science ®Google Scholar
• Buzzi MG. Pathways to the best fit of triptans for migraine patients. Cephalalgia 2008;28:S21-7
   PubMedGoogle Scholar
• Pascual J, Vila C, McGown CC. Almotriptan: a review of 10 years' clinical experience. Expert Rev Neurother 2010;10:1505-17
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Massiou H, Cabarrocas X, Randomized double-blind trial comparing the efficacy and tolerability of almotriptan and zolmitriptan in the acute treatment of migraine. Eur J Neurol 2005;12:S195
   Google Scholar
• Mathew NT, Finlayson G, Smith TR, Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache 2007;47:189-98
   PubMed Web of Science ®Google Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449-55
   PubMed Web of Science ®Google Scholar
• Freitag FG, Finlayson G, Rapoport AM, Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 2007;47:519-30
   PubMed Web of Science ®Google Scholar